זלבוראף
roche pharmaceuticals (israel) ltd - vemurafenib - טבליות מצופות פילם - vemurafenib 240 mg - vemurafenib - vemurafenib - zelboraf is indicated for the treatment of brafv600 mutation-positive unresectable or metastatic melanoma.
קסאלקורי 200 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
קסאלקורי 200 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
קסאלקורי 250 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
קסאלקורי 250 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 250 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.
אינלייטה 1 מג
pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 1 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.
אינלייטה 5 מג
pfizer pharmaceuticals israel ltd - axitinib - טבליות מצופות פילם - axitinib 5 mg - axitinib - axitinib - for the treatment of advanced renal cell carcinoma (rcc) after failure of one prior systemic therapy.
ג'קאבי 5 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ג'קאבי 15 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
ג'קאבי 20 מג
novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.